A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
